Trial
NCT03230097
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Psychotic Disorders
Intervention
BI 409306
Why stopped
disruption due to COVID-19
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-14